Endothelial cell surface binding sites

Endothelial cell surface binding sites refers to a heterogeneous group of proteins and molecules on the vascular endothelium that serve as attachment or clearance points for various ligands, including thrombolytic agents and endogenous regulators of angiogenesis. These sites include specific receptors such as Annexin A2, Low-density lipoprotein receptor-related protein 1 (LRP1), and mannose receptors, which are primarily responsible for the rapid clearance of tissue plasminogen activator (tPA) from the bloodstream [1, 3]. In the development of cardiovascular therapeutics, drugs like Reteplase have been engineered to lack the specific domains (finger and EGF domains) that bind to these endothelial sites, thereby significantly extending their plasma half-life compared to native tPA [1]. Furthermore, this term is used in the context of anti-angiogenic research, where the binding site for angiostatin was identified as ectopic ATP synthase located on the endothelial cell surface, which mediates the inhibition of endothelial cell proliferation [2, 4]. These sites also play a role in the endocytosis of cationic molecules and the regulation of local fibrinolytic activity [3]. Consequently, these binding sites represent both a challenge for drug longevity and a target for therapeutic intervention in cancer and cardiovascular diseases.

Other names

Endothelial binding sitesEndothelial clearance receptorsEndothelial cell surface receptorsEndothelial cell surface binding proteins

Binding to these sites typically mediates the rapid clearance of proteins from the circulation or triggers specific cellular responses, such as the inhibition of angiogenesis through the binding of angiostatin to surface-localized ATP synthase.